Валеология: Здоровье, Болезнь, Выздоровление. 2019; : 242-246
ИЗМЕНЕНИЯ ЦЕНТРАЛЬНОЙ ГЕМОДИНАМИКИ ПОСЛЕ ДЕНЕРВАЦИИ РЕНАЛЬНЫХ АРТЕРИЙ У ПАЦИЕНТА С ГИПЕРТЕНЗИВНОЙ КАРДИОМИОПАТИЕЙ
Аннотация
Основы современной терапии базируются на сложной схеме патогенеза хронической сердечной недостаточности. В настоящее время установлены нейрогормональные механизмы развития хронической сердечной недостаточности, в котором ведущая роль принадлежит повышению активности симпатической нервной системы. В последнее десятилетие во всем мире активно изучается эффективность эндоваскулярной денервации ренальных артерий в снижении
артериального давления у пациентов с резистентной артериальной гипертензией посредством снижения активности системы ренин-ангиотензин-альдостерон. Представлен клинический случай симпатической ренальной денервации у пациента с хронической сердечной недостаточностью, обусловленной гипертензивной кардиомиопатией.
Список литературы
1. Allman, K. C., et al., Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol, 2002. 39 (7): p. 1151-8.
2. Hunt, S. A., C. American College of, and G. American Heart Association Task Force on Practice, ACC / AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol, 2005. 46 (6): p. e1-82.
3. Baliga R. R., G. M., Pitt B. , Management of Heart Failure. 2008: Springer.
4. Ponikowski, P., et al., 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. Rev Esp Cardiol (Engl Ed), 2016. 69 (12): p. 1167.
5. E. Gronda, E. V., A Costea, Heart Failure Management: The Neural Pathways. 2015: Springer.
6. Rundqvist, B., et al., Increased cardiac adrenergic drive precedes generalized sympathetic activation in human heart failure. Circulation, 1997. 95(1): p. 169-75.
7. Triposkiadis, F., et al., The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol, 2009. 54 (19): p. 1747-62.
8. Packer, M., The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol, 1992. 20 (1): p. 248-54.
9. Schrier, R. W. and W. T. Abraham, Hormones and hemodynamics in heart failure. N Engl J Med, 1999. 341 (8): p. 577-85.
10. Jessup, M., et al., 2016 ESC and ACC/AHA/HFSA heart failure guideline update - what is new and why is it important? Nat Rev Cardiol, 2016. 13 (10): p. 623-8.
11. Yancy, C. W., et al., 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology / American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation, 2017. 136 (6): p. e137-e161.
12. Azizi, M., et al., Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet, 2015. 385(9981): p. 1957-65.
13. Bohm, M., et al., First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension. Hypertension, 2015. 65 (4): p. 766-74.
14. Krum, H., et al., Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet, 2014. 383 (9917): p. 622-9.
15. Rosa, J., et al., Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension, 2015. 65 (2): p. 407-13.
16. Aripov, M., et al., Individualised renal artery denervation improves blood pressure control in Kazakhstani patients with resistant hypertension. Kardiol Pol, 2017. 75 (2): p. 101-107.
Valeology: Health - Illnes - recovery. 2019; : 242-246
CHANGES IN CENTRAL HEMODYNAMICS AFTER RENAL DENERVATION IN PA- TIENT WITH HYPERTENSIVE CARDIOMYOPATHY
Abstract
The foundations of modern therapy are based on a complex pattern of the pathogenesis of chronic heart failure. Currently established neurohormonal mechanisms for the development of chronic heart fail-ure, in which the leading role belongs to an increase in the activity of the sympathetic nervous system. In the last decade, the effectiveness of endovascular denervation of the renal arteries in reducing blood pressure in patients with resistant arterial hypertension, by reducing the activity of the renin-angiotensin-aldosterone system, has been actively studied all over the world. A clinical case of sympathetic renal denervation in a patient with chronic heart failure caused by hypertensive cardiomyopathy is presented.
References
1. Allman, K. C., et al., Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol, 2002. 39 (7): p. 1151-8.
2. Hunt, S. A., C. American College of, and G. American Heart Association Task Force on Practice, ACC / AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol, 2005. 46 (6): p. e1-82.
3. Baliga R. R., G. M., Pitt B. , Management of Heart Failure. 2008: Springer.
4. Ponikowski, P., et al., 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. Rev Esp Cardiol (Engl Ed), 2016. 69 (12): p. 1167.
5. E. Gronda, E. V., A Costea, Heart Failure Management: The Neural Pathways. 2015: Springer.
6. Rundqvist, B., et al., Increased cardiac adrenergic drive precedes generalized sympathetic activation in human heart failure. Circulation, 1997. 95(1): p. 169-75.
7. Triposkiadis, F., et al., The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol, 2009. 54 (19): p. 1747-62.
8. Packer, M., The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol, 1992. 20 (1): p. 248-54.
9. Schrier, R. W. and W. T. Abraham, Hormones and hemodynamics in heart failure. N Engl J Med, 1999. 341 (8): p. 577-85.
10. Jessup, M., et al., 2016 ESC and ACC/AHA/HFSA heart failure guideline update - what is new and why is it important? Nat Rev Cardiol, 2016. 13 (10): p. 623-8.
11. Yancy, C. W., et al., 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology / American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation, 2017. 136 (6): p. e137-e161.
12. Azizi, M., et al., Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet, 2015. 385(9981): p. 1957-65.
13. Bohm, M., et al., First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension. Hypertension, 2015. 65 (4): p. 766-74.
14. Krum, H., et al., Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet, 2014. 383 (9917): p. 622-9.
15. Rosa, J., et al., Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension, 2015. 65 (2): p. 407-13.
16. Aripov, M., et al., Individualised renal artery denervation improves blood pressure control in Kazakhstani patients with resistant hypertension. Kardiol Pol, 2017. 75 (2): p. 101-107.
